{"id":"carfilzomib-lenalidomide-dexamethasone","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Thrombocytopenia"},{"rate":"30-50","effect":"Anemia"},{"rate":"20-40","effect":"Neutropenia"},{"rate":"20-30","effect":"Peripheral neuropathy"},{"rate":"30-40","effect":"Fatigue"},{"rate":"20-30","effect":"Diarrhea"},{"rate":"20-30","effect":"Infection"},{"rate":"15-25","effect":"Hyperglycemia"},{"rate":"5-15","effect":"Cardiac toxicity"}]},"_chembl":{"chemblId":"CHEMBL451887","moleculeType":"Protein","molecularWeight":"719.92"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Carfilzomib is a proteasome inhibitor that prevents degradation of pro-apoptotic proteins, triggering cancer cell death. Lenalidomide is an immunomodulatory drug that enhances T-cell proliferation and redirects cereblon E3 ligase to degrade oncogenic proteins. Dexamethasone is a corticosteroid that reduces inflammation and enhances the anti-myeloma effects of the other agents. Together, they target multiple pathways in myeloma cell survival and proliferation.","oneSentence":"This combination therapy kills multiple myeloma cells by inhibiting the proteasome (carfilzomib), modulating cereblon-mediated protein degradation (lenalidomide), and suppressing inflammatory cytokines (dexamethasone).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:58.367Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (newly diagnosed and relapsed/refractory)"}]},"trialDetails":[{"nctId":"NCT04268498","phase":"PHASE2","title":"A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2020-02-11","conditions":"Multiple Myeloma","enrollment":310},{"nctId":"NCT01297764","phase":"PHASE1, PHASE2","title":"A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2011-04","conditions":"Multiple Myeloma","enrollment":17},{"nctId":"NCT06152575","phase":"PHASE3","title":"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-02-08","conditions":"Multiple Myeloma","enrollment":492},{"nctId":"NCT06615479","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2025-03-12","conditions":"Relapsed or Refractory Multiple Myeloma (RRMM)","enrollment":440},{"nctId":"NCT05438043","phase":"PHASE3","title":"A Study of Daratumumab","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-12-15","conditions":"Multiple Myeloma","enrollment":500},{"nctId":"NCT01572480","phase":"PHASE2","title":"Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-05-29","conditions":"Multiple Myeloma","enrollment":55},{"nctId":"NCT03361306","phase":"PHASE2","title":"LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2018-01-09","conditions":"Multiple Myeloma","enrollment":15},{"nctId":"NCT03729804","phase":"PHASE3","title":"Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2019-05-07","conditions":"Multiple Myeloma","enrollment":250},{"nctId":"NCT02659293","phase":"PHASE3","title":"Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2016-04-26","conditions":"Multiple Myeloma","enrollment":180},{"nctId":"NCT06892522","phase":"PHASE1, PHASE2","title":"A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-06-30","conditions":"Multiple Myeloma","enrollment":440},{"nctId":"NCT05572515","phase":"PHASE3","title":"A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-03-29","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":614},{"nctId":"NCT03031730","phase":"PHASE1","title":"Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-14","conditions":"Plasmacytoma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":35},{"nctId":"NCT04113018","phase":"PHASE2","title":"Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2020-01-10","conditions":"Multiple Myeloma","enrollment":39},{"nctId":"NCT05497804","phase":"PHASE2","title":"Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-09-22","conditions":"ISS Stage III Plasma Cell Myeloma, Multiple Myeloma","enrollment":17},{"nctId":"NCT04430894","phase":"PHASE2","title":"KRDI in Transplant-Eligible MM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-07-10","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT04822337","phase":"PHASE1, PHASE2","title":"Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2021-05-19","conditions":"Multiple Myeloma","enrollment":70},{"nctId":"NCT02969837","phase":"PHASE2","title":"Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2017-07-10","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT05675319","phase":"PHASE3","title":"Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy","status":"TERMINATED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2023-03-03","conditions":"Multiple Myeloma","enrollment":28},{"nctId":"NCT02343042","phase":"PHASE1, PHASE2","title":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2015-10","conditions":"Multiple Myeloma","enrollment":300},{"nctId":"NCT03290950","phase":"PHASE2","title":"A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-09-25","conditions":"Multiple Myeloma","enrollment":75},{"nctId":"NCT02970747","phase":"","title":"Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients","status":"COMPLETED","sponsor":"iOMEDICO AG","startDate":"2016-10-25","conditions":"Multiple Myeloma in Relapse","enrollment":359},{"nctId":"NCT02937571","phase":"PHASE1, PHASE2","title":"High Dose Carfilzomib for Newly Diagnosed Myeloma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-10","conditions":"Multiple Myeloma","enrollment":29},{"nctId":"NCT03500445","phase":"PHASE2","title":"Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2019-02-13","conditions":"Myeloma, Multiple Myeloma","enrollment":75},{"nctId":"NCT03004287","phase":"PHASE2","title":"2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2017-07-01","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT01559935","phase":"PHASE2","title":"Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2012-04-19","conditions":"Multiple Myeloma","enrollment":74},{"nctId":"NCT01863550","phase":"PHASE3","title":"Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2013-12-06","conditions":"Plasma Cell Myeloma","enrollment":1087},{"nctId":"NCT04191616","phase":"PHASE2","title":"Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet","status":"COMPLETED","sponsor":"Amgen","startDate":"2020-08-06","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":54},{"nctId":"NCT03314636","phase":"PHASE2","title":"Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oslo University Hospital","startDate":"2018-03-16","conditions":"Myeloma","enrollment":53},{"nctId":"NCT03934684","phase":"PHASE4","title":"Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-09-16","conditions":"Relapsed Refractory Multiple Myeloma","enrollment":101},{"nctId":"NCT06409702","phase":"PHASE4","title":"Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-06-12","conditions":"Newly Diagnosed, High Risk, MRD","enrollment":59},{"nctId":"NCT01816971","phase":"PHASE2","title":"Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2013-01","conditions":"Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma","enrollment":76},{"nctId":"NCT03412565","phase":"PHASE2","title":"A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-26","conditions":"Multiple Myeloma","enrollment":265},{"nctId":"NCT03556332","phase":"PHASE2","title":"A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-07-02","conditions":"Multiple Myeloma","enrollment":41},{"nctId":"NCT01998971","phase":"PHASE1","title":"A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02-18","conditions":"Multiple Myeloma","enrollment":240},{"nctId":"NCT06140966","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2023-10-20","conditions":"Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma","enrollment":54},{"nctId":"NCT06913192","phase":"PHASE1","title":"Efficacy of Sequential BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Newly Diagnosed Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Xuzhou Medical University","startDate":"2025-04-01","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT04483739","phase":"PHASE3","title":"Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Myeloma Network B.V.","startDate":"2020-09-25","conditions":"Multiple Myeloma","enrollment":302},{"nctId":"NCT02405364","phase":"PHASE2","title":"Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2014-02","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT05669989","phase":"PHASE2","title":"International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-04-05","conditions":"Plasma Cell Myeloma","enrollment":70},{"nctId":"NCT04096066","phase":"PHASE3","title":"A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione EMN Italy Onlus","startDate":"2019-07-01","conditions":"Multiple Myeloma, New Diagnosis Tumor","enrollment":84},{"nctId":"NCT02203643","phase":"PHASE2","title":"Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mario Boccadoro","startDate":"2015-02","conditions":"MULTIPLE MYELOMA (MM)","enrollment":477},{"nctId":"NCT04934475","phase":"PHASE3","title":"MInimal Residual Disease Adapted Strategy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Intergroupe Francophone du Myelome","startDate":"2021-12-08","conditions":"Multiple Myeloma","enrollment":791},{"nctId":"NCT03859427","phase":"PHASE3","title":"A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-05-08","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":454},{"nctId":"NCT03104842","phase":"PHASE2","title":"Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2017-08-15","conditions":"Multiple Myeloma","enrollment":246},{"nctId":"NCT02891811","phase":"PHASE2","title":"Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy","status":"COMPLETED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2017-03-10","conditions":"Multiple Myeloma","enrollment":124},{"nctId":"NCT03289299","phase":"PHASE2","title":"Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"International Myeloma Foundation","startDate":"2018-05-25","conditions":"Smoldering Multiple Myeloma","enrollment":87},{"nctId":"NCT03224507","phase":"PHASE2","title":"Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2018-03-14","conditions":"Multiple Myeloma","enrollment":123},{"nctId":"NCT02188368","phase":"PHASE2","title":"Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients","status":"TERMINATED","sponsor":"Oncotherapeutics","startDate":"2014-07-07","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT03673826","phase":"PHASE2","title":"Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2018-11-19","conditions":"Smouldering Myeloma","enrollment":58},{"nctId":"NCT02294357","phase":"PHASE2","title":"Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib","status":"TERMINATED","sponsor":"Oncotherapeutics","startDate":"2014-12","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT02206425","phase":"PHASE1, PHASE2","title":"Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Oncotherapeutics","startDate":"2014-09","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT03948035","phase":"PHASE3","title":"Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wuerzburg University Hospital","startDate":"2018-08-28","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":576},{"nctId":"NCT02336815","phase":"PHASE2","title":"Selinexor Treatment of Refractory Myeloma","status":"COMPLETED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2015-05-26","conditions":"Multiple Myeloma","enrollment":202},{"nctId":"NCT03651128","phase":"PHASE3","title":"Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2019-04-16","conditions":"Multiple Myeloma","enrollment":381},{"nctId":"NCT03416374","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-02-18","conditions":"Relapsed and/or Refractory Multiple Myeloma","enrollment":45},{"nctId":"NCT01080391","phase":"PHASE3","title":"Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-07-14","conditions":"Relapsed Multiple Myeloma","enrollment":792},{"nctId":"NCT03891355","phase":"PHASE2","title":"Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL","status":"UNKNOWN","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2019-09-30","conditions":"Mantle Cell Lymphoma","enrollment":16},{"nctId":"NCT03742297","phase":"PHASE3","title":"Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2018-10-22","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":462},{"nctId":"NCT02415413","phase":"PHASE2","title":"Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2015-05","conditions":"Smoldering Multiple Myeloma","enrollment":90},{"nctId":"NCT05060627","phase":"PHASE1, PHASE2","title":"Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide","status":"RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2021-12-20","conditions":"Relapsed Multiple Myeloma","enrollment":60},{"nctId":"NCT05509374","phase":"PHASE2","title":"Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2021-10-28","conditions":"Multiple Myeloma","enrollment":33},{"nctId":"NCT05497102","phase":"PHASE2","title":"Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2021-11-08","conditions":"Multiple Myeloma","enrollment":58},{"nctId":"NCT05495620","phase":"","title":"Long-term KRd in Relapsed and/or Refractory Multiple Myeloma","status":"UNKNOWN","sponsor":"Dong-A University Hospital","startDate":"2022-08-01","conditions":"Multiple Myeloma in Relapse, Multiple Myeloma, Refractory","enrollment":300},{"nctId":"NCT03375567","phase":"NA","title":"Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma With Carfilzomib Lenalidomide Dexamethasone","status":"COMPLETED","sponsor":"Yale University","startDate":"2018-06-04","conditions":"Multiple Myeloma","enrollment":28},{"nctId":"NCT04065789","phase":"PHASE2","title":"Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients","status":"COMPLETED","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2018-05-02","conditions":"Myeloma Multiple, Myeloma, Plasma-Cell, Myeloma-Multiple","enrollment":41},{"nctId":"NCT04288765","phase":"PHASE3","title":"Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma","status":"WITHDRAWN","sponsor":"Grupo Cooperativo de Hemopatías Malignas","startDate":"2020-03-01","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT02128230","phase":"PHASE2","title":"UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2014-06-10","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT03606577","phase":"PHASE2","title":"An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2019-07-30","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT02036502","phase":"PHASE1","title":"A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-02-14","conditions":"Multiple Myeloma","enrollment":77},{"nctId":"NCT01402284","phase":"PHASE2","title":"Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-07-21","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT02335983","phase":"PHASE1","title":"Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-04-30","conditions":"Multiple Myeloma","enrollment":107},{"nctId":"NCT02265510","phase":"PHASE1, PHASE2","title":"An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2014-09-10","conditions":"Solid Tumors, Advanced Malignancies, Metastatic Cancer","enrollment":83},{"nctId":"NCT03815279","phase":"PHASE2","title":"A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)","status":"ENROLLING_BY_INVITATION","sponsor":"Landspitali University Hospital","startDate":"2019-06-24","conditions":"Multiple Myeloma, Smoldering Multiple Myeloma","enrollment":80},{"nctId":"NCT01554852","phase":"PHASE3","title":"Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients","status":"UNKNOWN","sponsor":"University of Leeds","startDate":"2010-05","conditions":"Multiple Myeloma","enrollment":4420},{"nctId":"NCT00603447","phase":"PHASE1","title":"Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma","status":"COMPLETED","sponsor":"Amgen","startDate":"2008-05","conditions":"Relapsed Multiple Myeloma","enrollment":84},{"nctId":"NCT02802163","phase":"PHASE1, PHASE2","title":"Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat","status":"WITHDRAWN","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-06","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT01029054","phase":"PHASE1, PHASE2","title":"Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2009-09","conditions":"Multiple Myeloma","enrollment":53},{"nctId":"NCT01537861","phase":"EARLY_PHASE1","title":"Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2012-06","conditions":"Multiple Myeloma","enrollment":7}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":52,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["KRd"],"phase":"phase_3","status":"active","brandName":"Carfilzomib Lenalidomide Dexamethasone","genericName":"Carfilzomib Lenalidomide Dexamethasone","companyName":"European Myeloma Network B.V.","companyId":"european-myeloma-network-b-v","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy kills multiple myeloma cells by inhibiting the proteasome (carfilzomib), modulating cereblon-mediated protein degradation (lenalidomide), and suppressing inflammatory cytokines (dexamethasone). Used for Multiple myeloma (newly diagnosed and relapsed/refractory).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}